Bayer snaps up biotech firm Vividion Therapeutics for $2 billion
Bayer AG is in talks to buy Vividion Therapeutics in a roughly $2 billion deal, enforcing new IPO plans for Vividion.
Login
X
- New Ventures
- Market Analysis
- Emerging Markets
- Technology
- Professional Services
- Media & Entertainment
- Manufacturing & Retail
- Logistics & Supply Chain
- Healthcare & Pharmaceutical
- Financial Services
- Energy
- Autos
- Aerospace & Defense
- Work-Life Balance
- Strategic Thinking
- Productivity
- Decision Making
- Communication
- Sustainability
- Success Story
- Power Players
- Philanthropy
- People
- Innovation
- CEO Magazine
